Calcium channel α2δ1 proteins mediate trigeminal neuropathic pain states associated with aberrant excitatory synaptogenesis. by Li, Kang-Wu et al.
UC Irvine
UC Irvine Previously Published Works
Title
Calcium channel α2δ1 proteins mediate trigeminal neuropathic pain states associated 
with aberrant excitatory synaptogenesis.
Permalink
https://escholarship.org/uc/item/69p4s53x
Journal
The Journal of biological chemistry, 289(10)
ISSN
0021-9258
Authors
Li, Kang-Wu
Yu, Yanhui Peter
Zhou, Chunyi
et al.
Publication Date
2014-03-01
DOI
10.1074/jbc.M114.548990
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Calcium Channel 21 Proteins Mediate Trigeminal
Neuropathic Pain States Associated with Aberrant Excitatory
Synaptogenesis*
Received for publication, January 11, 2014, and in revised form, January 22, 2014 Published, JBC Papers in Press, January 23, 2014, DOI 10.1074/jbc.M114.548990
Kang-Wu Li‡1, Yanhui Peter Yu§1, Chunyi Zhou§, Doo-Sik Kim‡2, Bin Lin‡, Kelli Sharp¶, Oswald Steward¶,
and Z. David Luo‡§¶3
From the Departments of ‡Anesthesiology and Perioperative Care and §Pharmacology and ¶Reeve-Irvine Research Center,
University of California School of Medicine, Irvine, California 92697
Background: Factors mediating orofacial neuropathic pain are not well defined.
Results:Trigeminal nerve injury-induced calcium channel 21 protein up-regulation in trigeminal ganglia and spinal complex
correlated with enhanced spinal presynaptic neurotransmission, excitatory synaptogenesis, and orofacial pain states.
Conclusion: This neuroplasticity may mediate orofacial neuropathic pain states by enhancing dorsal horn excitatory synaptic
neurotransmission.
Significance: This reveals a mechanism underlying orofacial neuropathic pain states.
To investigate a potential mechanism underlying trigeminal
nerve injury-induced orofacial hypersensitivity, we used a rat
model of chronic constriction injury to the infraorbital nerve
(CCI-ION) to study whether CCI-ION caused calcium channel
21 (Cav21) protein dysregulation in trigeminal ganglia and
associated spinal subnucleus caudalis and C1/C2 cervical dorsal
spinal cord (Vc/C2). Furthermore, we studied whether this neu-
roplasticity contributed to spinal neuron sensitization and neu-
ropathic pain states. CCI-ION caused orofacial hypersensitivity
that correlated with Cav21 up-regulation in trigeminal gan-
glion neurons and Vc/C2. Blocking Cav21 with gabapentin, a
ligand for the Cav21 proteins, or Cav21 antisense oligode-
oxynucleotides led to a reversal of orofacial hypersensitivity,
supporting an important role of Cav21 in orofacial pain proc-
essing. Importantly, increasedCav21 inVc/C2 superficial dor-
sal horn was associated with increased excitatory synaptogen-
esis and increased frequency, but not the amplitude, of
miniature excitatory postsynaptic currents in dorsal horn neu-
rons that could be blocked by gabapentin. Thus, CCI-ION-in-
duced Cav21 up-regulation may contribute to orofacial neu-
ropathic pain states through abnormal excitatory synapse
formation and enhanced presynaptic excitatory neurotransmit-
ter release in Vc/C2.
Chronic pain is a common clinical syndrome representing a
major decrease in the quality of daily life of patients and creates
enormous social and economical problems. It has been esti-
mated that about 50 and 10% of people in the United States
suffering from localized and widespread chronic pain, respec-
tively (1). Among chronic pain conditions, orofacial pain, which
can derive from different etiologies including orofacial inflam-
mation and tissue andnerve injuries, can be themost severe and
debilitating. Chronic pain states, such as pain sensations result-
ing from stimuli that are normally innocuous (allodynia) and
increased pain sensations to suprathreshold stimuli (hyperalge-
sia), tend to be persistent even in the absence of noxious stimuli
and in some cases refractory to conventional analgesic treat-
ments. In addition, the use of opioids and other current pain
medications is usually limited by problems related to tolerance,
addiction, or other nonspecific side effects, which could be life-
threatening. Ideally, target-specific therapeutic agents could
provide an efficient and safe means of pain relief. Unfortu-
nately, the molecular mechanisms associated with neuropathic
orofacial pain are poorly understood (2), and as a consequence,
the availability of target-specific, effective pharmacological
agents for chronic orofacial pain management is very limited.
Clinical data have shown that neuropathic orofacial pain is
sensitive to treatments with gabapentin (2, 3), a drug that binds
to the calcium channel21 (Cav21)4 and22 (Cav22) sub-
units (4, 5). The Cav2 is a structural subunit of the voltage-
gated calcium channels important for their functional assembly
and expression (6–10). Four Cav2 genes have been identified
that encode the Cav21, Cav22, Cav23, and Cav24 sub-
units, respectively (11–13). These subunits have distinct tissue-
specific expression patterns, suggesting their diversified func-
tions in different tissues (5). Findings from a non-orofacial
neuropathic pain model have indicated that peripheral nerve
injury induces up-regulation of Cav21, but not Cav22 (14),
in dorsal root ganglia and lumbar dorsal spinal cord that corre-
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lates with development of neuropathic pain states sensitive to
gabapentin (15–17) without affecting normal nociceptive
responses (18–21). However, the detailed mechanism underly-
ingCav21 dysregulation in neuropathic pain processing is not
clear. In addition, it is not clear whether trigeminal nerve injury
causes Cav21 dysregulation in the trigeminal spinal complex,
which differs in structure from that of non-orofacial sensory
systems. In this study, we examined whether trigeminal nerve
injury induced Cav21 dysregulation in an orofacial neuro-
pathic painmodel and if sowhat is the underlying role of altered
Cav21 expression in mediating spinal neuron sensitization
and development of orofacial neuropathic pain states.
MATERIALS ANDMETHODS
Experimental Animals—Male adult Sprague-Dawley rats
(160–250 g) were used in this study. Animals were housed in
groups of three to four in cages with soft bedding with free
access to food and water under a 12/12-h light-dark cycle. All
animals were acclimated in their cages for 3–4 days before any
experiments, which were carried out according to protocols
approved by the Institutional Animal Care and Use Committee
of the University of California, Irvine.
Surgery—All surgeries were performed under an operation
microscope (MZ95, Leica Microsystems, Wetzlar, Germany).
Ratswere anesthetizedwith isoflurane (4% for induction, 2% for
maintenance) in O2, shaved above the left eye, and maintained
in a prone position. The surgical procedure of chronic constric-
tion injury to the infraorbital nerve (CCI-ION), a branch of the
trigeminal nerve, was performed similar to that described by
Kernisant et al. (22). Briefly, an anterior-posterior skin incision
above the left eye was made following the curve of the frontal
bone. The fascia and muscles were then gently pushed laterally
from the bone until the contents of the orbit could be gently
retracted laterally so that the ION lying on the maxillary bone
could be visualized. The ION was then gently freed from sur-
rounding connective tissues. Two loose ligatures (6-0 silk) were
placed 3–4 mm apart around the ION using fine forceps and a
suture-loaded needlewith a bended tip and then loosely ligated.
The incision was closed with a 5-0 silk suture, and the rat was
recovered on a warm heating pad. In the sham-operated rats,
the same procedure was used to expose the left ION, but the
ION was not ligated.
For intrathecal catheter implantation, a catheter (PE-10 tub-
ing, 8 cm long) was prepared such that the inserting end of the
tubingwas blockedwith superglue, and holes1.0 cm from the
blocked tip were made with a 30-gauge needle. This allowed
the insertion of the distal end of the catheter into the subarach-
noid space so drugs could be delivered through the holes near
the spinal subnucleus caudalis and C1/C2 cervical dorsal spinal
cord (Vc/C2) region. Two loose overhand knots, which do not
occlude the tubing, were tied and secured by superglue; onewas
1.5 cm from the indwelling tip for stopping further insertion of
the catheter through the dura mater, and the other was 2.0 cm
from the indwelling tip for securing the catheter in place by
suturing. A small incision was made on the back of the neck,
and the posterior atlantooccipital membrane was exposed after
tissueswere gently retracted caudally from the occipital bone.A
small nick was made in the posterior atlantooccipital mem-
brane (dura mater) using a 25-gauge needle, and a catheter
(sterilized PE-10 tubing filled with saline) was inserted gently
and caudally (0.5 cm) and sutured with muscle ligaments
together before closing muscle and skin layers with 5-0 silk
sutures. After recovery from anesthesia on a warm pad, rats
were returned to their cages and housed individually. Rats were
sacrificed at a designated time after behavioral studies, TG and
dorsal Vc/C2 were collected, and either used immediately for
biochemical studies or kept at80 °C until use.
Behavioral Tests—Orofacial behavioral tests as described by
Vos et al. (23) were performed blindly 1 day before and at des-
ignated times after CCI-ION surgeries. For gabapentin treat-
ments, behavioral tests started before and then 30min and 1, 2,
4, 6, 8, and 24 h after the injection. For daily intrathecal injec-
tion of Cav21 antisense or mismatched oligodeoxynucle-
otides, the rats were tested before each daily injection and at
designated times after the last injection.
The rats were shaved at and near the vibrissal pad under light
isoflurane anesthesia 1 day before the testing and placed indi-
vidually in plastic cages for acclimatization at least 1 h before
the testing. During this period, the experimenter reached
slowly into the cage to touch the cage wall slightly with a plastic
rod similar to the handle of a von Frey filament. The behavioral
test started after the rats were calm.When necessary, the accli-
matization period was extended.
Mechanical sensitivity was tested with a series of graded von
Frey filaments (numbers 3.61, 3.84, 4.08, 4.31, 4.56, 4.74, 4.93,
and 5.18 equivalent to 0.4, 0.6, 1.0, 2.0, 4.0, 6.0, 8.0, and 15 g of
force, respectively), starting with the 4.31 von Frey filament,
and the 50% withdrawal thresholds were determined by the
up-down method (24). Briefly, the examiner applied the von
Frey filament slowly to the ION territory, near the center of the
vibrissal pad, with sufficient force to bend the filament slightly
for 2–3 s. A positive response was considered if one or more of
the following behaviors occurred: 1) a brisk withdrawal reac-
tion in which a rat pulled briskly backward, 2) escape/attack in
which a rat avoided further contact with the filament either by
passively moving its body away from the stimulation to assume
a crouching position against the cage wall or sometimes with
the head buried under the body or attacked the filament actively
through biting and grabbing movements, and 3) asymmetric
face grooming in which a rat displayed an uninterrupted series
of at least three face wash strokes directed to the stimulated
facial area often preceded by a brisk withdrawal reaction. Pres-
ence of a positive response led to the use of the next filament
with a lower stimulating force. Absence of a positive response
led to the use of the next filament with a higher stimulating force.
This testing paradigm continued until responses to six von Frey
stimuli, starting from the one before the first change in response
(either negative or positive), were measured. The responses were
then converted into a 50% withdrawal threshold value using the
following formula: 50% withdrawal threshold  10(X kd)/104
whereX is the value of the final von Frey hair used in log units, k is
the tabular value for the pattern of positive/negative responses
from Chaplan et al. (25), and d is the mean difference between
stimuli in log units. When consecutive positive or negative
responseswere observed at the end of a stimulus session, scores of
0.25 or 15 g were assigned, respectively. As reported by other
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research groups, a small percentage of CCI-ION rats displayed
milder bilateral orofacial hypersensitivities postinjury (23, 26).
These animals were excluded from the studies.
To determine whether locomotor functions were altered in
rats following gabapentin treatments, the Basso, Beattie, Bres-
nahan Locomotor Rating Scale (27) and the rotarod test were
performed blindly in saline or gabapentin (100mg/kg intraperi-
toneally)-treated rats. For the Basso, Beattie, Bresnahan Loco-
motor Rating Scale test, animals were acclimated to their test-
ing environment daily for a week before the testing. The
locomotor functions were examined based on a scale focused
on evaluating consistent coordination between the front and
hind limbs including paw position, toe clearance, trunk stabil-
ity, and tail position (28). For the rotarod (Economex, Colum-
bus Instruments) test, each rat was placed on the rotarod for
seven trials. The first two trials were for training, and then data
from the last five trials were averaged. The maximum time for
each trial was 120 s. The initial speed of the rotarod was set to 4
rpm, and the acceleration rate was 0.1 rpm.
Western Blots—Tomeasure protein expression levels, frozen
TG and dorsal Vc/C2 samples were extracted in 50 mM Tris
buffer, pH 8.0 containing 0.5% Triton X-100, 150 mM NaCl, 1
mM EDTA, and protease inhibitors. Cell extracts were sub-
jected to denaturing NuPAGE Tris acetate gel (Invitrogen)
electrophoresis and then electrophoretically transferred to
PVDFmembranes. 5% low fat milk in Tris-buffered saline con-
taining 0.1% Tween 20 was used to block nonspecific binding
sites for at least 1 h at room temperature. The Cav21 mono-
clonal antibodies (mouse, Sigma-Aldrich; 1:1000) or Cav22
polyclonal antibodies (rabbit, Alomone Labs Ltd., Israel; 1:200)
in phosphate-buffered saline containing 0.1% Tween 20 were
incubated with the membranes for 1 h at room temperature or
overnight at 4 °C. After washing, the antibody-protein com-
plexes were detected using appropriate secondary antibodies
linked to horseradish peroxidase. Antibodies against -actin
(mouse, Novus Biologicals, LLC, Littleton, CO; 1:10,000) were
used for loading controls. The antibody-protein complexes
were visualized by chemiluminescent reagents. The band den-
sities were quantified by either imaging quantification or den-
sitometry within the linear range of the film sensitivity curve.
Cav2 protein levels were normalized by taking the ratios of
the Cav2 band density to that of -actin within each sample
before cross-sample comparisons to calculate the percent
changes in Cav2 protein levels in the experimental groups
compared with that in the control groups. Variations in Cav2
band densities in the control groups (contralateral side) were
determined by comparing each band density with the mean of
the band densities from at least two different control samples
run in the sameWestern blot after taking the ratios of Cav2 to
-actin band densities.
Drug Treatments—Gabapentin (Endo Life Sciences, Inc. Farm-
ingdale, NY) was dissolved in sterile saline and intraperitoneally
injected (50–100 mg/kg; 1-ml total volume) into CCI-ION rats
with allodynia after 3 weeks of CCI-ION. The antisense (AGCC-
ATCTTCGCGATCGAAG) oligodeoxynucleotides against the
Cav21 gene (GenBankTM accession number M86621) and the
mismatched control (CGATACCTCGCTGGCTAAAG) were
synthesized commercially with phosphorothioatemodification
on three nucleotides at each end to increase its stability
(GeneLink, Hawthorne, NY). The oligodeoxynucleotides were
precipitated, washed in 75% ethanol, and dissolved in sterile
saline before injections. Cav21 antisense or mismatched oli-
godeoxynucleotides were intrathecally injected for 4 days (50
g/10 l/rat/day) through the catheter into allodynic rats
(started after 3 weeks of CCI-ION) followed by flushing with
saline (5 l to compensate for tubing dead volume). The same
volume of saline was injected as a control. A daily von Frey
filament test was performed before the daily injection and after
the final injection.
Immunohistochemistry—Vc/C2 spinal cord and TG samples
were collected from three animals in each group after 1- and
3-week CCI-ION and 3-week sham surgeries. Samples were
fixed in 4% paraformaldehyde overnight, cryoprotected in 30%
sucrose, thenmounted in optimal cutting tissuemedium (OCT,
Sakura Fintech, Torrance, CA), and sectioned into 10-mslices
by a cryostat (CM1900, LeicaMicrosystems). The thin sections
were pretreated with heat-based antigen retrieval and then
incubated for 2 days at 4 °C in Antibody Diluent Solution
(Dako, Carpinteria, CA) with combinations of primary anti-
bodies from different species against proteins of interest
including Cav21 (rabbit polyclonal, Thermo Fisher Scientific
Inc., Waltham, MA or mouse monoclonal, Sigma-Aldrich),
Vglut2 (guinea pig polyclonal, Synaptic Systems, Goettingen,
Germany), PSD95 (rabbit polyclonal, Invitrogen), and synapto-
physin (SYN; goat polyclonal, Santa Cruz Biotechnology, Dal-
las, TX). Control staining was done in parallel with omission of
the primary antibody. After washing, the sections were incu-
bated for 2 h at room temperature with respective Alexa Fluor
488 orAlexa Fluor 594 secondary antibodies. Isolectin B4 (IB4)-
positive staining was detected with Alexa Fluor 488-conjugated
IB4 (Invitrogen). Stained sections were then preserved using
Vectashield Hard Set Mounting Medium containing DAPI for
nucleus staining (Vector Laboratories, Inc., Burlingame, CA)
and coverslipped. Images were taken using a Zeiss LSM710 or
Zeiss LSM780 confocal microscope (University of California
IrvineOptical Biology Core) in stacks of 14 consecutive 0.3-m
Z-sections. Images were then cropped down to three to seven
consecutive Z-sections with the best signal and merged (as
specified below). Merged images were used for analysis using
Volocity (Version 6.0, PerkinElmer Life Sciences).
Sensory neurons in captured images of TG sections (merged
stacks of seven consecutive Z-sections of 0.3 m each, 100 m
apart, and 10 images/side/rat from three rats) were identified
basedon theirmorphologyandnucleus size andmanually selected
by drawing the longest line across each cell with a nucleus using
theVolocity line function.Backgroundsubtractionwasperformed
by subtracting the average fluorescence intensity of the neuron
with the lowest fluorescence intensity in each image.Only profiles
with Cav21 immunoreactive intensity at least 1-fold over the
baseline average intensitywere analyzed. Sizes of immunoreactive
cells were quantified using Volocity.
Fluorescent immunoreactivity from rat Vc/C2 sections was
analyzed after normalization of background threshold among
control (contralateral side) samples from different sets of
experiments using the Volocity Percentage Intensity function,
and the same background threshold was used for both the con-
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tralateral and injury sides for each set of experiments. Cav21
immunoreactivity was analyzed from merged stacks of seven
consecutive Z-sections of 0.3meach, 100mapart, and three
images/side/rat from three rats. Captured images from Vglut2/
Cav21-co-stained samples (merged stacks of three consecu-
tive Z-sections of 0.3 m each, 100 m apart, and nine images/
side/rat from three rats in each group) were analyzed to
determine the number of total Vglut2, Vglut2/Cav21, and
Vglut2/Cav21 puncta. SYN/Cav21-co-stained samples
(merged stacks of three consecutive Z-sections of 0.3 m each,
100 m apart, and three images/side/rat from three rats) were
analyzed for total SYN, SYN/Cav21, or SYN/Cav21
puncta. Vglut2/PSD95-co-stained samples (merged stacks of
three consecutive Z-sections of 0.3meach, 100mapart, and
six images/side/rat from three rats) were analyzed for total
PSD95 or Vglut2/PSD95 puncta. Data from the ipsilateral
side were compared with date from the contralateral side.
Electrophysiological Recording on Vc/C2 Slices—Vc/C2 was
collected from animals deeply anesthetized with isoflurane.
Transverse slices (300 m) were cut with a Vibratome
(VT1200) in an ice-cold (4 °C) sucrose solution containing 230
mM sucrose, 26 mM NaHCO3, 2.5 mM KCl, 1.25 mM NaH2PO4,
0.5mMCaCl2, 10mMMgSO4, and 10mM glucose, pH 7.4, 290–
305 mosmol/liter, equilibrated with 95% O2 and 5% CO2. The
slices were incubated for 1 h before recording in an artificial
cerebrospinal fluid containing 130 mM NaCl, 3 mM KCl, 2 mM
CaCl2, 2mMMgCl2, 1.25mMNaH2PO4, 26mMNaHCO3, and 10
mM glucose, pH 7.4, 295–305 mosmol/liter, which was continu-
ouslyequilibratedwith95%O2and5%CO2.Electrodesmade from
borosilicate glass (World Precision Instruments, Sarasota, FL)
with a horizontal electrode puller (P-97, Sutter Instrument Co.,
Novato, CA) had a resistance of 5–7 megaohms when filled with
an intracellular solution containing135 mM potassium gluconate,
5 mM KCl, 5 mM EGTA, 0.5 mM CaCl2, 10 mM HEPES, 2 mM
Mg-ATP, and 0.1 mM GTP, pH 7.4, 295–300 mosmol/liter. The
flow rate of oxygenated artificial cerebrospinal fluid in the record-
ing chamber was adjusted to 1 ml/min. Neurons in the Vc/C2
dorsal horn were visualized with an infrared differential interfer-
ence contrastmicroscope (FN1,Nikon Instruments, Inc.,Melville,
NY) and a charge-coupled device camera (Andor Clara, Andor
Technology, SouthWindsor, CT).
-Amino-3-hydroxyl-5-methylisoxazole-4-propionic
acid (AMPA) receptor-mediated miniature excitatory postsyn-
aptic currents (mEPSCs) were recorded at a 70-mV mem-
brane holding potential at 32 0.5 °C in the presence of tetro-
dotoxin (1 M; Sigma), strychnine (1 M; Sigma), bicuculline
(30 M; Research Biochemicals, Inc., Natick, MA), and amino-
phosphonovalerate (50 mM; Research Biochemicals, Inc.,
Natick, MA) to block tetrodotoxin-sensitive Na, glycinergic,
GABAergic, and N-methyl-D-aspartate (NMDA) currents,
respectively. At this holding potential, over 90% of dorsal horn
neuron mEPSCs are AMPA receptor-mediated because they
are sensitive to blockade by 6-cyano-7-nitroquinoxaline-2,3-
dione, an AMPA receptor antagonist (29). NMDA receptor-
mediated mEPSCs were not examined because they are not
activated at this holding potential because of voltage-depen-
dentMg2 blockade (30), and they only represent less than 10%
of the mEPSCs even at a depolarizing potential to remove the
Mg2 blockade (29). Series resistance (8–15 megaohms) was
monitored periodically during the recording, and cells with
15% changes were excluded from analysis. For experiments
involving gabapentin treatments, the same neurons were
recorded before treatment, during the 10-min gabapentin
treatment, and after 15-min washout. Recording signals were
filtered at 2 kHz and digitized at a sampling rate of 5 kHz using
a low noise data acquisition system (Digidata 1440A,Molecular
Devices).
Statistics—A p value 0.05 indicated significance deter-
mined by variance analyses for multigroup comparisons or by
two-tailed, unpaired Student’s t tests for pairwise comparisons
as indicated.
RESULTS
Trigeminal Nerve Injury Induced Up-regulation of the Cal-
cium Channel Cav21 Subunit Proteins That Correlated with
Orofacial Tactile Allodynia—Todeterminewhether trigeminal
nerve injury induced up-regulation of the Cav21 gene and if
so whether it correlated with development of orofacial neuro-
pathic pain, we examined Cav21 expression levels in trigem-
inal ganglia and Vc/C2 in an orofacial neuropathic pain model
derived from CCI-ION (23). As indicated in Fig. 1, unilateral
CCI-ION resulted in an initial orofacial hyposensitive state as
indicated by an initial increase in orofacial thresholds (to the
15-g cutoff maximal thresholds) to stimuli in the injury side for
10 days postinjury. This was followed by an orofacial hyper-
sensitive state shown as increased orofacial sensitivity (or
reduced threshold) to von Frey filament stimulation (about 3
weeks postinjury) in the injury side compared with the non-
injury side and sham-operated rats. These CCI-ION-induced
abnormal, biphasic orofacial sensitivities were also reported in
the original study describing this model (23). The allodynic
state lasted for about 7–8 weeks followed by a gradual recovery
in the injured rats.
If CCI-ION also inducedCav21 dysregulation that played a
role in orofacial pain processing, one would expect to see a
correlation between changes in Cav21 expression in TG
and/or Vc/C2 and orofacial allodynia development. To test this
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FIGURE 1. CCI-ION led to development of orofacial tactile allodynia in
adult male rats. Orofacial sensitivity to von Frey filament stimulation was
tested in thewhisker pad area of rats before and at the designated times after
CCI-ION or sham operations. Data presented are themeans S.E. (error bars)
from five to seven rats in each group.C, contralateral to injury; Ip, ipsilateral to
injury. *, p  0.05; #, p  0.001 compared with preinjury level by two-way
analysis of variance with Bonferroni post-tests.
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hypothesis, we examined the expression level of Cav21 in TG
and Vc/C2 at different stages of orofacial allodynia develop-
ment: (i) 1 week postinjury but before the onset of allodynia, (ii)
3 weeks postinjury when the injured rats displayed severe allo-
dynia, and (iii) 10 weeks postinjury when the injured animals
recovered from allodynia. As shown in Fig. 2 (A and B), CCI-
ION induced Cav21 up-regulation in TG but no change in
Vc/C2 before the onset of orofacial allodynia (1week post-CCI-
ION). However, CCI-ION induced Cav21 up-regulation in
both TG and Vc/C2 at the orofacial allodynia stage (3 weeks
post-CCI-ION) without altering the levels of Cav22 (Fig. 2C),
which also binds gabapentin (5). When the CCI-ION rats were
recovered from the allodynia states (10 weeks post-CCI-ION),
injury-induced Cav21 expression levels returned to a level
similar to the levels in the non-injury side. This temporal cor-
relation between injury-induced Cav21 up-regulation and
allodynia suggests that increased Cav21 may play a critical
role in orofacial neuropathic pain processing.
Localization of Injury-inducedCav21 inCCI-IONRatswith
Orofacial Allodynia—To determine the location of injury-in-
duced Cav21 expression in TG and Vc/C2 at the orofacial
neuropathic pain stage, we examined Cav21 immunoreactiv-
ity profiles in thin sections of TG and Vc/C2 samples from
3-week CCI-ION rats with tactile allodynia in the injury side.
Data from confocal immunofluorescent staining indicated that
the basal level of Cav21 immunoreactivity in the non-injury
side was relatively high in small and some medium size TG
neurons but low in large TG neurons. CCI-ION induced a
reduction in the number of the smallest profiles (15 m in
diameter) that were Cav21-immunoreactive. This could be
due to reduced Cav21 expression or dying back of injured
small sensory fibers (31). However, CCI-ION increased the
number of Cav21-immunoreactive profiles over 25 m in
diameter with a trend of more pronounced increases in
larger diameter profiles (Fig. 3). This suggests that CCI-ION
induced Cav21 dysregulation in different sizes of sensory
neurons.
Basal level Cav21 immunoreactivity was detectable in
superficial dorsal horn of Vc/C2 (Fig. 4A, Cav21,Contra.) and
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the inner portion of which co-localized with non-peptidergic
IB4-positive sensory fiber terminals projecting to inner lamina
II of the superficial dorsal horn (Fig. 4A, IB4, Cav21/IB4,Con-
tra.) (32–35). Three weeks after CCI-ION, the intensity of
Cav21 immunoreactivity was increased significantly in the
superficial, but not deep, dorsal horn of Vc/C2 in the injury
(ipsilateral) side compared with that in the non-injury (con-
tralateral) side (Fig. 4, A and B). The increased Cav21-immu-
noreactive intensity in the injury side was mainly due to an
increase of surface area of positive Cav21 immunoreactivity
(Fig. 4C) and a small but significant increase in average intensity
of Cav21 immunoreactivity (Fig. 4D). This pattern of Cav21
dysregulation is similar to that reported in a spinal nerve injury
model in which Cav21 is induced in dorsal root ganglion neu-
rons and then translocated to their central terminals in the
superficial dorsal horn of lumbar spinal cord (14, 36). Indeed,
CCI-ION-induced Cav21 up-regulation in TG neurons pre-
ceded that in dorsal Vc/C2 (Fig. 2, A and B). Together, it is
possible that CCI-ION induces Cav21 up-regulation in TG
neurons followed by its translocation to their central terminals
in Vc/C2 superficial dorsal horn.
Gabapentin Treatment in CCI-ION Rats Blocked Injury-in-
duced Allodynia—To confirm that up-regulated Cav21 is
involved in the processing of orofacial neuropathic pain, we
injected gabapentin, a drug that binds to the Cav21 proteins
(4) and has antiallodynia properties in patients (37–39) and
animal models (15–17, 40, 41), intraperitoneally into CCI-ION
rats with established allodynia to see whether this treatment
could reverse CCI-ION-induced allodynia. Bolus intraperito-
neal injection of 50 mg/kg gabapentin had a small and statisti-
cally not significant reversal of CCI-ION-induced tactile allo-
dynia. However, increasing the gabapentin dose to 100 mg/kg
resulted in a significant reversal of injury-induced orofacial
allodynia (Fig. 5A) similar to that observed in other centrally
(28) or peripherally induced (15, 41) neuropathic pain models.
The gabapentin effects lasted for approximately 6 h, which is
similar to the therapeutic duration of the drug. There were no
detectable side effects, such as impairedmotor functions (Fig. 5,
B and C), from the gabapentin treatments. These data support
thatCCI-ION-inducedCav21 up-regulation is highly likely to
be involved in allodynia processing.
Intrathecal Treatment with Cav21 Antisense Oligodeoxy-
nucleotides in CCI-ION Rats Resulted in Reversals of Allodynia
and Up-regulated Cav21 Proteins in Vc/C2—To further
determine whether CCI-ION-induced Cav21 up-regulation
played a critical role in mediating tactile allodynia, we injected
Cav21 antisense or mismatched oligodeoxynucleotides (50
g/rat/day) or saline intrathecally through the catheter into the
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FIGURE 4. Localization of CCI-ION-induced Cav21 immunoreactivity in Vc/C2. Immunostaining was performed in Vc/C2 samples collected from 3-week
CCI-ION rats with orofacial hypersensitivity in the injury side. A, representative Cav21 immunoreactivity (red) in injury (Ipsi.) and non-injury sides (Contra.) of
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Vc/C2 region of CCI-ION rats for 4 consecutive days, starting
after 3 weeks of CCI-ION when the injured rats had developed
allodynia, to see whether antisense treatment could block or
diminish CCI-ION-induced allodynia by diminishing elevated
Cav21 levels. As indicated in Fig. 6, intrathecal treatments
with the antisense, but notmismatched, oligodeoxynucleotides
resulted in a time-dependent reversal of tactile allodynia. A
similar injection of saline (equal volume) did not cause allo-
dynia reversal (42). The antisense effects had an onset time of 2
days, peaked approximately 5 days after treatment initiation (1
day after the last injection), and lasted for over 2 days after the
last injection. To determine whether the antisense effects were
due to blockade of CCI-ION-induced Cav21 up-regulation,
we examined Cav21 protein levels in dorsal Vc/C2 and TG
samples collected from CCI-ION rats 1 day after the last treat-
ment with Cav21 antisense or mismatched oligodeoxynucle-
otides or saline, which correlated with the peak antiallodynic
effects of the antisense oligodeoxynucleotides. Data from
Western blot analyses indicated that treatments with antisense
oligodeoxynucleotides, but not with mismatched oligodeoxy-
nucleotides or saline, caused a small and statistically not signif-
icant reversal of the injury-induced increase of Cav21 in TG
(Fig. 7A). However, similar treatments with antisense oligode-
oxynucleotides blocked injury-induced Cav21 up-regulation
in dorsal Vc/C2 (Fig. 7B). This correlation in antisense-
mediated blockade between injury-induced allodynia and
Vc/C2 Cav21 up-regulation supports that CCI-ION-induced
Cav21 up-regulation in dorsal Vc/C2 plays a critical role in
allodynia development.
Increased Cav21 in Vc/C2 Superficial Dorsal Horn Corre-
latedwith Increased Excitatory Synaptogenesis inCCI-IONRats
with Orofacial Allodynia—Cav21 proteins have been impli-
cated to play a critical role in mediating aberrant excitatory
synaptogenesis in the central nervous system (43). To deter-
mine whether CCI-ION led to increased excitatory synapto-
genesis associated with Cav21 up-regulation and orofacial
hypersensitivity, we examined the degree of co-localization
betweenCav21 immunoreactivity and puncta of an excitatory
presynaptic glutamatergic terminal marker, Vglut2, in superfi-
cial dorsal horn of Vc/C2 from CCI-ION rats at time points
correlated with the absence (1 week postinjury) or presence (3
weeks postinjury) of orofacial allodynia. Vglut2 was selected
because knocking out Vglut2, but not Vglut1, from sensory neu-
rons abolished or reduced nerve injury-induced tactile and cold
allodynia in peripheral nerve injury models (44–46). Although
Vglut3 has been shown to be present in a unique subset of sen-
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sory neurons that may play a distinct role in nerve injury-in-
duced behavioral hypersensitivity (47), it was not examined due
to the lack of specific antibodies commercially available to us.
Our data indicated that the total number of Vglut2-positive
(Vglut2) puncta increased significantly in the injury side of
3-week, but not 1- week, CCI-ION Vc/C2 samples (Fig. 8, A
and B). By separating Vglut2 puncta into Cav21-positive
(Cav21) andCav21-negative (Cav21) groups, we found
that all of the increased immunoreactive puncta were both
Vglut2 and Cav21. In contrast, the number of Vglut2 but
Cav21 puncta showed a slight decrease, whichmight be due
to dying back of injured nerves that led to loss of their synaptic
terminals. Importantly, the numbers of Vglut2/Cav21
puncta were not changed in Vc/C2 samples taken from 1-week
CCI-ION or 3-week sham rats, which did not have orofacial
allodynia (Fig. 8, A and B).
Similarly, the total punctum counts of SYN, another pre-
synaptic marker, were also significantly increased in Vc/C2
superficial dorsal horn of the injury side compared with that
from the non-injury side 3 weeks post-CCI-ION (Fig. 9, A
and B). These changes were mainly associated with Cav21
up-regulation because only SYN-positive (SYN) and
Cav21 immunoreactive puncta were increased, whereas
SYN but Cav21 punctum counts remained unchanged
in the injury side compared with those from the non-injury
side (Fig. 9, A and B).
To determine whether CCI-ION-increased excitatory syn-
apses in superficial dorsal horn ofVc/C2were functional, which
should contain postsynaptic elements, we examined the co-lo-
calization of immunoreactivity for Vglut2 and a postsynaptic
marker, PSD95, in 3-week CCI-ION Vc/C2 samples. Our data
showed thatCCI-ION induced a significant increase in the total
number of PSD95-immunoreactive puncta (Fig. 9, C and D)
that correlated with a similar increase in PSD95-immunoreac-
tive puncta thatwere alsoVglut2-immunoreactive (Fig. 9,C and
E). Together, these findings support that CCI-ION-induced
Vglut2-positive excitatory synapses are functional as they con-
tain both pre- and postsynaptic elements.
Increased Frequency of Gabapentin-sensitive Excitatory Post-
synaptic Currents in Vc/C2 Superficial Dorsal Horn Neurons
Correlated with Orofacial Allodynia Development in CCI-ION
Rats—To confirm whether CCI-ION-induced Vc/C2 Cav21
up-regulation contributed to orofacial behavioral hypersensi-
tivity through a central mechanism related to Vc/C2 neuron
sensitization, we examinedmEPSCs inVc/C2 superficial dorsal
horn neurons fromCCI-ION rats either 1 or 3 weeks post-CCI-
ION, time points correlating with either the absence or pres-
ence of allodynia in injured rats, respectively. Because dorsal
horn neuron mEPSCs are induced by presynaptic glutamate
release, changes in its frequency or amplitude reflect a presyn-
aptic or postsynaptic mechanism, respectively (29, 48). As indi-
cated in Fig. 10, neither the frequency nor amplitude of
mEPSCs differed significantly in Vc/C2 superficial dorsal horn
neurons between sham and CCI-ION rats at the 1-week time
point (Fig. 10, A–D). However, the frequency, but not the
amplitude, of mEPSCs in Vc/C2 superficial dorsal horn neu-
rons was significantly increased in CCI-ION rats compared
with that in sham control rats 3 weeks postinjury (Fig. 10, E–H).
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FIGURE 7. Cav21 protein levels in TG and Vc/C2 after treatment with antisense andmismatched oligodeoxynucleotides. Cav21 protein levels in TG
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In addition, the increased mEPSC frequency could be blocked
by gabapentin dose-dependently (Fig. 10, I and J). Themaximal
percent inhibition of mEPSCs by gabapentin was similar to the
percent increase of mEPSCs in neurons from injured rats (Fig.
10, G and J). Together, these data suggest that increased
Cav21 in the Vc/C2 region is highly likely to mediate the
development of orofacial hypersensitivity by enhancing presyn-
aptic excitatory transmitter release, which can be normalized
by gabapentin.
DISCUSSION
Orofacial neuropathic pain is a devastating disorder with
limited efficacious therapeutic options due to the fact that its
underlyingmechanisms are notwell defined. Findings from this
study have indicated that injury to the trigeminal nerve leads to
up-regulation of Cav21, but not Cav22, in TG and associ-
ated dorsal Vc/C2 spinal cord that correlates with Vc/C2 aber-
rant excitatory synaptogenesis, enhanced presynaptic excit-
atory inputs, and neuropathic pain state development. Both
orofacial allodynia and Cav21 up-regulation in dorsal
Vc/C2 spinal cord can be blocked by treatments with
intrathecal Cav21 antisense, but not mismatched, oligode-
oxynucleotides. In addition, gabapentin treatment can nor-
malize CCI-ION-induced Vc/C2 neuron sensitization and
reverse orofacial allodynic states. Together, these findings
support that trigeminal nerve injury-induced Cav21 dys-
regulation may play a critical role in mediating orofacial
hypersensitivity through a mechanism involving aberrant
excitatory synaptogenesis and elevated presynaptic excit-
atory neurotransmitter release.
The temporal correlation between Vc/C2 Cav21 dysregu-
lation (Fig. 2) and orofacial hypersensitivity development (Fig.
1) only in a later stage (3 weeks) postinjury supports that mech-
anisms underlying acute pathological changes and chronic pain
states post-trigeminal nerve injury are distinct. Thus, this
model may be useful in studying mechanistic transitions from
acute nerve injury to chronic pain development. In addition,
the 3-week onset time of allodynia development in this orofa-
cial pain model is much longer than that in the spinal nerve
ligation injurymodel, which develops peak allodynia within the
1st week postinjury (15, 16, 49, 50) including the time required
for anterograde transport of elevated Cav21 from dorsal root
ganglion sensory neurons to their presynaptic central axon ter-
minals in lumbar dorsal spinal cord (14, 36). This discrepancy
suggests that, in addition to structural differences between the
trigeminal and peripheral nervous systems, trigeminal nerve
injury-induced pain states may bemediated by amore complex
mechanism than simply Cav21 up-regulation followed by its
translocation from TG to Vc/C2. It is possible that the slow
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onset of allodynia in the CCI-ION model reflects the time
required for some pathological changes to occur inVc/C2 post-
CCI-ION, such as dysregulation of factors that are unique to
CCI-ION and critical for allodynia development in a later stage.
These unique factors may play a critical role in regulating tri-
geminal nerve injury-induced Cav21 up-regulation or its
translocation from injured trigeminal neurons to their central
axon terminals in superficial dorsal horn of Vc/C2. Alterna-
tively, these factors may serve as critical cofactors in Cav21-
mediated orofacial pain states.
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FIGURE 9. CCI-ION-induced Vc/C2 Cav21 immunoreactivity correlated with excitatory synaptogenesis. Co-immunostaining of Cav21 with synaptic
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(Contra.) side by Student’s t test. Contra., contralateral to injury; Ipsi., ipsilateral to injury.
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Although our data could not exclude any possible contribu-
tion of a postsynaptic mechanism to CCI-ION-induced orofa-
cial neuropathic pain states, our behavioral pharmacology,
immunostaining, and electrophysiology data support that CCI-
ION-induced Cav21 up-regulation plays an active role in
mediating orofacial hypersensitivity mainly through a presyn-
aptic mechanism. This is supported by findings from a non-
orofacial neuropathic pain model in which increased Cav21
expression in dorsal root ganglion sensory neurons leads to
spinal neuron sensitization through enhanced presynaptic
excitatory neurotransmitter release (29, 51). Although it is
technically impossible to ligate the dorsal roots of trigeminal
nerves betweenTGandVc/C2 to block this pathway, ourWest-
ern blot data indicate that Cav21 up-regulation in TG pre-
cedes that in Vc/C2 postinjury (Fig. 2), and immunostaining
data support that increased Cav21 in Vc/C2 is co-localized
with presynaptic markers (Figs. 8 and 9). In addition, recording
data support that CCI-ION-induced Vc/C2 neuron sensitiza-
tion is drivenmainly by enhanced presynaptic excitatory inputs
when the CCI-ION rats display behavioral hypersensitivity
(Fig. 10, E–H).
In combination with recent findings that Cav21 is the neu-
ronal receptor for astrocyte-secreted thrombospondins in
mediating excitatory synaptogenesis in the central nervous sys-
tem (43) and that CCI-ION also induces thrombospondin
expression in Vc/C2 that contributes to orofacial pain process-
ing (42), our findings are consistent with the notion that ele-
vated presynaptic Cav21 in the Vc/C2 regionmay cause aber-
rant excitatory synaptogenesis (Figs. 8 and 9), leading to spinal
neuron sensitization (Fig. 10) and neuropathic pain states (Fig.
1). This is supported by our Western blot data showing that
Cav21 up-regulation is diminished inTG, but abolished in the
Vc/C2 region, after Cav21 antisense, but not mismatched,
oligodeoxynucleotide treatments (Fig. 7), which correlates with
diminished orofacial allodynia in injured rats (Fig. 6).
Currently, we donot know the underlyingmechanism for the
transient increase in orofacial sensitivity in the contralateral
side within the 1st week of CCI-ION (Fig. 1). It is possible that
injury-induced bilateral changes, such as activation of spinal
microglia and astrocytes and increased cytokines as reported in
other inflammatory and neuropathic pain models (52–56), are
responsible for the contralateral effects. These factors, how-
ever, failed to elicit behavioral hypersensitivity within the first 2
weeks postinjury in the injury side. This could be due, but not
limited, to the following reasons. 1) During this hyposensitive
stage, degenerating sensory fibers may contribute to sensory
input distortions, such as partial or complete numbness (23). 2)
Degenerating and/or regenerating sensory fibers may be
actively involved in reorganization of sensory circuits in Vc/C2
but less sensitive to modulations by these factors. 3) A central
sensitization state that is required for mediating the behavioral
hypersensitivity in the later stage is still under development in
this period. These can be supported by our findings that neither
abnormalVc/C2neuron sensitization (Fig. 10,A–D) nor behav-
ioral hypersensitivity (Fig. 1) in the injury side is detectable in
this period.
The fast action of gabapentin in reversing increased mEPSC
frequency in Vc/C2 neurons (Fig. 10, I and J) and neuropathic
allodynia (Fig. 5A) in this model, however, supports that bind-
ing of gabapentin to Cav21 is critical in normalizing Vc/C2
neuron sensitization and behavioral hypersensitivity. Because
the effects of gabapentin are use-dependent (21, 57, 58), it is
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FIGURE 10. CCI-ION enhanced presynaptic excitatory neurotransmitter
release that could be blocked by gabapentin and correlated with orofa-
cial allodynia.A–D,mEPSCs in superficial dorsal hornneuronsofVc/C2 spinal
cord slices 1-week post sham or post-CCI-ION. A and B, representative traces
of mEPSCs from neurons in the injury side of sham (A) and CCI-ION (B) rats. C
and D, summary of mEPSC frequency (C) and amplitude (D) in superficial
dorsal horn neurons from the injury side of sham and CCI-ION rats (means
S.E. (error bars) from 17 neurons of three sham rats and 19 neurons of three
CCI-ION rats).n.s., not significantbyStudent’s t test. E–H,mEPSCs in superficial
dorsal horn neurons of Vc/C2 spinal cord slices 3-weeks post sham or post-
CCI-ION. E and F, representative traces of mEPSCs from neurons in the injury
side of sham (E) and CCI-ION (F) rats. G and H, summary of mEPSC frequency
(G) andamplitude (H) in superficial dorsal hornneurons from the injury sideof
shamandCCI-ION rats (means S.E. (error bars) from28 neurons each of four
sham rats and four CCI-ION rats, respectively). n.s., not significant; *, p 0.05
compared with sham control by Student’s t test. I, representative mEPSC
traces before (upper panel), during (middle panel) 10-min 100M gabapentin
(GBP) perfusion, and after 15-min washout (lower panel). J, gabapentin inhi-
bitionof enhancedmEPSC frequency inVc/C2 superficial dorsal hornneurons
of the injury side from 3-week CCI-ION rats (means  S.E. (error bars) from
three to four neurons in each group). The dotted line represents the baseline
level of mEPSC frequency in superficial dorsal horn neurons from sham con-
trol rats. **,p0.01 comparedwith thepretreatment level by Student’s t test.
Cav21 Mediates Trigeminal Neuropathic Pain
MARCH 7, 2014•VOLUME 289•NUMBER 10 JOURNAL OF BIOLOGICAL CHEMISTRY 7035
 by guest on February 18, 2020
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
possible that CCI-ION-induced Cav21 in Vc/C2 is contribut-
ing to the functional integrity of hyperexcitable synapses and
formation of abnormal excitatory synapses, both of which are
critical in maintaining Vc/C2 neuron sensitization and orofa-
cial behavioral hypersensitivity. However, only about 32% of
nerve injury-induced neuropathic pain patients have at least
moderate pain relief after gabapentin treatment (59). The rea-
son for the variation in efficacy of gabapentin in neuropathic
pain relief is not clear. It may be due, but not limited, to the
following possibilities. First, gabapentin efficacy in neuropathic
pain reliefmay correlate with the level of Cav21 dysregulation
among pathological conditions, which could vary significantly.
This is supported by data from animal studies (15). Second,
other cofactors, such as thrombospondins, that interact with
Cav21 in promoting excitatory CNS synaptogenesis (43) may
also play a critical role in neuropathic pain processing (42, 60).
Blocking the interactions of Cav21 with other factors, such as
thrombospondins, by gabapentin would be critical in normal-
izing the activity of pathologically modified synapses in the
short term and blocking the progression of abnormal synapto-
genesis in the long term (43). Detailed investigations are under-
way to test these possibilities underlying the role of Cav21 in
promoting neuropathic pain states.
In conclusion, we presented data here to support that CCI-
ION leads toCav21 up-regulation in dorsal Vc/C2 spinal cord
that may contribute to the development of orofacial neuro-
pathic pain states through a central mechanism involving
abnormal sensitization of Vc/C2 neurons by enhanced excit-
atory synaptogenesis and presynaptic release of excitatory neu-
rotransmitters. Identifying and blocking new cofactors of this
pathway alone or in combination with gabapentin may provide
specific therapeutic benefits for orofacial neuropathic pain
management.
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